Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EPS (Weighted Average and Diluted) (2022 - 2025)

Entrada Therapeutics has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.94 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.94 for Q4 2025, down 2250.0% from a year ago — trailing twelve months through Dec 2025 was -$3.46 (down 288.04% YoY), and the annual figure for FY2025 was -$3.47, down 306.55%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.94 at Entrada Therapeutics, up from -$1.06 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for TRDA hit a ceiling of $1.55 in Q2 2024 and a floor of -$1.06 in Q3 2025.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.55 (2025), compared with a mean of -$0.31.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 423.81% in 2024 and later crashed 2250.0% in 2025.
  • Entrada Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.78 in 2022, then soared by 64.1% to -$0.28 in 2023, then surged by 85.71% to -$0.04 in 2024, then crashed by 2250.0% to -$0.94 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.94 (Q4 2025), -$1.06 (Q3 2025), and -$1.04 (Q2 2025) per Business Quant data.